Clinical trial

Evaluation of Pharmacokinetic / Pharmacodynamic and Tolerance Assessment of Dermal Administration of Beta-lactams in the Elderly

Name
BETALACUTANE
Description
The route of subcutaneous administration of drugs has become a common practice in some specialties (palliative care, geriatrics). This is an alternative to oral, sublingual, rectal or intravenous Many drugs are used by subcutaneous route but few clinical studies evaluating the level of scientific relevance justifies their use. The purpose of this study is to assess: 1. / Determine that there is no difference between the subcutaneously compared to intravenous administration in terms of dosage and serum PK / PD of Beta lactam objectives in a geriatric population. 2. / The safety and lack of toxicity of administrations subcutaneously. Advantages disadvantages * easy Of establishment * Simplicity Monitoring and manipulation * Reduced Risk of infection * No Risk of venous thrombosis * Lower cost Simple -Technique for support at home taking * Limitation Aggressive gestures * multiplicity Of all possible injection sites * Technique Of choice for agitated patients or confused -Risk of localized edema (\<1000mL / 24 / site) * Use Impossible for some drugs * Risk Discomfort and intolerance at the injection site A practical study was conducted among 382 physicians (289 geriatricians and 93 infectious disease specialists). Among them 97.5% reported regular use of the subcutaneous route for the administration of antibiotics. Declarative criteria pretend curb the use of this route was the lack of data Pk / Pd (61.2%); the absence of marketing authorization for the subcutaneous route (34.5%); the absence of serum assay available (2.1%).
Trial arms
Trial start
2015-06-26
Estimated PCD
2022-08-30
Trial end
2023-03-06
Status
Terminated
Treatment
Assessment of dermal administration of Beta-Lactams
Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
Size
2
Primary endpoint
Assessment of change of residual concentration of Beta-Lactam antibiotic
Minute 30, hour 24, Day 7. Then once a Week 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12
Eligibility criteria
Inclusion Criteria: * Geriatric Population (≥ 75 years) * Infection may cause bacteremia or not: Gram-negative bacilli and gram-positive cocci susceptible to beta-lactam Exclusion Criteria: * Patient Refusal expressed or legal guardian * polymicrobial infection
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 2, 'type': 'ACTUAL'}}
Updated at
2023-03-08

1 organization

1 product

2 indications

Indication
Beta-Lactams
Indication
Aged Subject